Document is current
Any future updates will be listed below
-
Authors
Fahmy, Monica https://orcid.org/0000-0002-5723-5607
Sylvester, Katelyn W.
Migliore, Mattia
Eguale, Tewodros
Fanikos, John
Connors, Jean M.
Goldhaber, Samuel Z.
-
Funding
Funding for this research was provided by:
MCPHS University Honor's Program
- License Information
-
More Information
Article History
Accepted: 10 January 2021
First Online: 9 April 2021
Compliance with ethical standards
:
: Katelyn W. Sylvester has acted as a consultant for Portola Pharmaceuticals, Inc. John Fanikos has served as a consultant for Portola, Inc. and Pfizer, Inc. Jean M. Connors has served as a consultant for Abbott, Anthos Therapeutics, Bristol-Myers Squibb, eXlthera, and Five Prime Therapeutics. She has also served on the Scientific Advisory Board of Anthos Therapeutics, Bristol-Myers Squibb, and eXlthera as well as provided research funding to the institution of CSL Behring. Samuel Z. Goldhaber has served as a consultant for Agile, Bayer, Boehringer-Ingelheim, and Pfizer, Inc. He has also participated in research with Bayer, Boehringer-Ingelheim, BMS, Boston Scientific, Daiichi, Janssen Pharmaceuticals, NHLBI, and Pfizer, Inc.
